Publications by authors named "Reuben Benjamin"

Claim this Profile
L
Lymphoma-derived extracellular vesicles inhibit CAR T cell function.
Khadiza Siddika, Katie R Flaherty, Reuben Benjamin, Anna Schurich, Molly S Cook

MicroPubl Biol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients.
Molly S Cook, Ellen King, Katie R Flaherty, Khadiza Siddika, Sophie Papa, Reuben Benjamin

Cell Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka, Reuben Benjamin

Blood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis).
María-Victoria Mateos, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Reuben Benjamin

Leukemia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are we there yet? CAR-T therapy in multiple myeloma.
Eitan Mirvis, Reuben Benjamin

Br J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
Maeve A O'Reilly, Lorna Neill, Simon M Collin, Neil Stone, Deborah Springell, Reuben Benjamin

Hemasphere· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Niels W C J van de Donk, Monique C Minnema, Bronno van der Holt, Fredrik Schjesvold, Ka Lung Wu, Reuben Benjamin

Lancet Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
Kai Rejeski, Marion Subklewe, Mahmoud Aljurf, Emmanuel Bachy, Adriana Balduzzi, Reuben Benjamin

Blood· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang-Ki Min

Clin Lymphoma Myeloma Leuk· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, Domenico Cozzetto, Despoina Papazoglou, Reuben Benjamin

J Clin Invest· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Kwee Yong, William Wilson, Ruth M de Tute, Marquita Camilleri, Karthik Ramasamy, Reuben Benjamin

Lancet Haematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Reuben Benjamin, Nitin Jain, Marcela V Maus, Nicolas Boissel, Charlotte Graham

Lancet Haematol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.
Sandra Dupouy, Ibtissam Marchiq, Thibaud Derippe, Maria Almena-Carrasco, Agnieszka Jozwik, Reuben Benjamin

Cancer Res Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Reuben Benjamin

Leukemia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Leena Halim, Kushal K Das, Daniel Larcombe-Young, Adam Ajina, Andrea Candelli, Reuben Benjamin

Front Immunol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Sosana Delimpasi, Maria Victoria Mateos, Holger W Auner, Maria Gavriatopoulou, Meletios A Dimopoulos, Reuben Benjamin

Am J Hematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Ana M Metelo, Agnieszka Jozwik, Le Anh Luong, Delaney Dominey-Foy, Charlotte Graham, Reuben Benjamin

Cancer Res Commun· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.
Andrea Kuhnl, Claire Roddie, Amy A Kirkwood, Tobias Menne, Maria Cuadrado, Reuben Benjamin

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
Charlotte Elizabeth Graham, Agnieszka Jozwik, Ruby Quartey-Papafio, Nikolaos Ioannou, Ana M Metelo, Reuben Benjamin

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Larysa Sanchez, Xavier Leleu, Jennifer L Beaumont, Hailin Yu, Stacie Hudgens, Reuben Benjamin

Am J Hematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Reuben Benjamin

Am J Hematol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
Beth Russell, Charlotte L Moss, Vallari Shah, Thinzar Ko Ko, Kieran Palmer, Reuben Benjamin

Br J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Reuben Benjamin

Am J Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W Auner, Xavier Leleu, Reuben Benjamin

J Hematol Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis